Freezing Equals Freezing? Performance of Two Cryoablation Devices in Concomitant Mitral Valve Repair

Abstract

Background Recent guidelines have recommended the addition of ablation in cardiac surgery for patients presenting with atrial fibrillation (AF). Currently available cryoablation devices use either nitrous oxide or argon gas as cooling agent. Our study aimed to compare success rates of two different devices currently available on the market and applied during concomitant cardiac surgery.

Methods Between 2009 and 2012, data were collected from 120 consecutive patients in whom either the aluminum cryoICE ablation probe (AtriCure, Inc., Cincinnati, Ohio, United States) using nitrous oxide or the stainless steel Cardioblate CryoFlexTM 10-S probe (Medtronic, Inc., Minneapolis, Minnesota, United States) using argon gas was applied for concomitant ablation procedures in minimally invasive mitral valve cases. Perioperative variables, myocardial injury biomarkers (MIBs) and Holter monitoring results were compared.

Results Perioperative variables such as sex, age, type, and duration of AF, procedure and cross-clamp times, and 30-day mortality did not significantly differ between the groups. Postoperative peak creatinine kinase MB (CK-MB) levels were significantly higher in the nitrous oxide group (p = 0.047). At a mean follow-up of 20 ± 13 months, freedom from AF was significantly higher in the nitrous oxide group (87%) compared with the argon group (71%, p = 0.044). Left atrial (LA) diameter and device used were the only predictors of failure of ablation (p = 0.029 and p = 0.018, respectively).

Conclusion The nitrous oxide–based aluminum probe revealed a better outcome than the argon-based stainless steel probe. Besides the cooling agent, probe material and probe-tissue interface might have contributed to the better performance of the cryoICE probe.

Keywords

arrhythmia therapy - ablation - minimally invasive surgery

Note

This manuscript has been accepted for presentation at the ISMICS meeting in Berlin, June 3–6, 2015.

• References

• 1 Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158 (3) 229-234
• 2 Cox JL, Schuessler RB, D'Agostino Jr HJ , et al. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991; 101 (4) 569-583
• 3 Weimar T, Schena S, Bailey MS , et al. The Cox-Maze procedure for lone atrial fibrillation: a single-center experience over 2 decades. Circ Arrhythm Electrophysiol 2012; 5 (1) 8-14
• 4 Weerasooriya R, Khairy P, Litalien J , et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?. J Am Coll Cardiol 2011; 57 (2) 160-166
• 5 Weimar T, Bailey MS, Watanabe Y , et al. The Cox-Maze IV procedure for lone atrial fibrillation: a single center experience in 100 consecutive patients. J Interv Card Electrophysiol 2011; 31 (1) 47-54
• 6 Weimar T, Vosseler M, Czesla M, Boscheinen M, Hemmer WB, Doll KN. Approaching a paradigm shift: endoscopic ablation of lone atrial fibrillation on the beating heart. Ann Thorac Surg 2012; 94 (6) 1886-1892
• 7 Doll N, Aupperle H, Borger M, Czesla M, Mohr FW. [Efficacy and safety of various energy sources and application techniques for the surgical treatment of atrial fibrillation]. Herzschrittmacherther Elektrophysiol 2007; 18 (2) 83-91
• 8 Weimar T, Lee AM, Ray S, Schuessler RB, Damiano Jr RJ. Evaluation of a novel cryoablation system: in vivo testing in a chronic porcine model. Innovations (Phila) 2012; 7 (6) 410-416
• 9 Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology 1998; 37 (3) 171-186
• 10 Gage AM, Montes M, Gage AA. Freezing the canine thoracic aorta in situ. J Surg Res 1979; 27 (5) 331-340
• 11 Phan K, Xie A, Tian DH, Shaikhrezai K, Yan TD. Systematic review and meta-analysis of surgical ablation for atrial fibrillation during mitral valve surgery. Ann Cardiothorac Surg 2014; 3 (1) 3-14
• 12 Rankin JS, He X, O'Brien SM , et al. The Society of Thoracic Surgeons risk model for operative mortality after multiple valve surgery. Ann Thorac Surg 2013; 95 (4) 1484-1490
• 13 Blomström-Lundqvist C, Johansson B, Berglin E , et al. A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). Eur Heart J 2007; 28 (23) 2902-2908
• 14 Martinez-Comendador J, Castaño M, Mosquera I , et al. Cryoablation of atrial fibrillation in cardiac surgery: outcomes and myocardial injury biomarkers. J Cardiothorac Vasc Anesth 2011; 25 (6) 1030-1035
• 15 Henry L, Ad N. The surgical treatment for atrial fibrillation: ablation technology and surgical approaches. Rambam Maimonides Med J 2013; 4 (3) e0021
• 16 Gillinov AM, Bhavani S, Blackstone EH , et al. Surgery for permanent atrial fibrillation: impact of patient factors and lesion set. Ann Thorac Surg 2006; 82 (2) 502-513 , discussion 513–514
• 17 Ad N, Suri RM, Gammie JS, Sheng S, O'Brien SM, Henry L. Surgical ablation of atrial fibrillation trends and outcomes in North America. J Thorac Cardiovasc Surg 2012; 144 (5) 1051-1060
• 18 Ad N, Holmes SD, Massimiano PS, Pritchard G, Stone LE, Henry L. The effect of the Cox-Maze procedure for atrial fibrillation concomitant to mitral and tricuspid valve surgery. J Thorac Cardiovasc Surg 2013; 146 (6) 1426-1434 , discussion 1434–1435
• 19 Calkins H, Kuck KH, Cappato R , et al; Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 2012; 9 (4) 632-696.e21
• 20 Damiano Jr RJ, Schwartz FH, Bailey MS , et al. The Cox-Maze IV procedure: predictors of late recurrence. J Thorac Cardiovasc Surg 2011; 141 (1) 113-121
• 21 Doll N, Borger MA, Fabricius A , et al. Esophageal perforation during left atrial radiofrequency ablation: is the risk too high?. J Thorac Cardiovasc Surg 2003; 125 (4) 836-842
• 22 Weimar T, Lee AM, Ray S, Schuessler RB, Damiano Jr RJ. Evaluation of a novel cryoablation system: in vitro testing of heat capacity and freezing temperatures. Innovations (Phila) 2012; 7 (6) 403-409
• 23 CRC Handbook of Chemistry and Physics. 79th ed. In: Lide DR. , ed. Boca Raton, FL: CRC Press; 1998
• 24 Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int 2005; 95 (9) 1187-1191
• 25 Hanke T, Charitos EI, Stierle U , et al. Twenty-four-hour Holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy: up to 12 months experience with a novel permanently implantable heart rhythm monitor device. Circulation 2009; 120 (11, Suppl): S177-S184